Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary KRW., Golubchik T., Aley PK., Ariani CV., Angus B., Bibi S., Blane B., Bonsall D., Cicconi P., Charlton S., Clutterbuck EA., Collins AM., Cox T., Darton TC., Dold C., Douglas AD., Duncan CJA., Ewer KJ., Flaxman AL., Faust SN., Ferreira DM., Feng S., Finn A., Folegatti PM., Fuskova M., Galiza E., Goodman AL., Green CM., Green CA., Greenland M., Hallis B., Heath PT., Hay J., Hill HC., Jenkin D., Kerridge S., Lazarus R., Libri V., Lillie PJ., Ludden C., Marchevsky NG., Minassian AM., McGregor AC., Mujadidi YF., Phillips DJ., Plested E., Pollock KM., Robinson H., Smith A., Song R., Snape MD., Sutherland RK., Thomson EC., Toshner M., Turner DPJ., Vekemans J., Villafana TL., Williams CJ., Hill AVS., Lambe T., Gilbert SC., Voysey M., Ramasamy MN., Pollard AJ.

DOI

10.1016/s0140-6736(21)00628-0

Type

Journal article

Journal

The Lancet

Publisher

Elsevier BV

Publication Date

04/2021

Volume

397

Pages

1351 - 1362

Permalink Original publication